SNOA vs. SXTP, CWBR, NTBL, CNSP, SLRX, ATXI, DRMA, CYTO, VRPX, and ONCO
Should you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include 60 Degrees Pharmaceuticals (SXTP), CohBar (CWBR), Notable Labs (NTBL), CNS Pharmaceuticals (CNSP), Salarius Pharmaceuticals (SLRX), Avenue Therapeutics (ATXI), Dermata Therapeutics (DRMA), Altamira Therapeutics (CYTO), Virpax Pharmaceuticals (VRPX), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.
Sonoma Pharmaceuticals (NASDAQ:SNOA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.
Sonoma Pharmaceuticals received 215 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 33.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
Sonoma Pharmaceuticals currently has a consensus target price of $3.25, suggesting a potential upside of 2,059.47%. 60 Degrees Pharmaceuticals has a consensus target price of $2.40, suggesting a potential upside of 997.39%. Given Sonoma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Sonoma Pharmaceuticals is more favorable than 60 Degrees Pharmaceuticals.
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Sonoma Pharmaceuticals.
60 Degrees Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -41.24%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.
2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 9.2% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.
Summary
60 Degrees Pharmaceuticals beats Sonoma Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Sonoma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonoma Pharmaceuticals Competitors List
Related Companies and Tools
